XULI WANG portrait
  • Assistant Professor (Tenure Track), Radiology Som
  • Assistant Professor, Radiology Som
801-581-6854

Research Statement

Dr. Wang has been assigned an independent and large laboratory space (approximately 1600 square feet) and private office in the Division of Radiobiology located in Research Park, the University of Utah. Currently the research activities in Wang laboratory include the development of novel biomaterials for imaging and therapy in hopes of improving diagnosis and treatment for diseases, particularly for advanced osteolytic cancers, including breast cancer, prostate cancer and multiple myeloma. The primary ongoing projects in Dr Wang's lab include: 1) Multimodality nanotherapeutics for cancer induced bone metastasis; 2) The development of biodegradable and biocompatible molecular imaging probes. These projects are currently sponsored by National Cancer Institute (NIH 1R01CA166941), the Department of Defense (DOD PC120872), and American Heart Association (11BGIA7430022), respectively.

Grants, Contracts & Research Gifts

  • An osteolytic stimuli-responsive nanotherapeutic system for bone metastases. PI: Xuli Wang. NIH/NCI, 05/10/2013 - 05/09/2018. Total project budget to date: $1,545,875.00
  • Targeted, On-demand Charge Conversional Nanotherapeutics for Advanced Prostate Cancer . PI: Xuli Wang. Department of Defense, 07/01/2013 - 06/30/2016. Total project budget to date: $335,250.00
  • Targeting NEK2 in Myeloma to Overcome Drug-resistance. PI: Fenghuang Zhan. Co-PI(s): Xuli Wang. Leukemia Lymphoma Society, 10/01/2011 - 09/30/2014. Total project budget to date: $600,000.00
  • Molecular Imaging Agents. PI: Xuli Wang. American Heart Association, 07/01/2011 - 06/30/2014. Total project budget to date: $140,000.00
  • Biocompatible, Biodegradable, and Enzymatic-Cleavable MRI Contrast Agents for Early Detection of Bone Metastatic Breast Cancer. PI: Xuli Wang. Department of Defense, 04/01/2011 - 03/31/2013. Total project budget to date: $112,000.00
  • Bone-Targeted Drug Delivery System. PI: Xuli Wang. Seed Grant, Utah BMT/Myeloma Program, University of Utah, 07/01/2010 - present. Total project budget to date: $20,000.00
  • Bone-Targeted Statin Delivery System. PI: Xuli Wang. Center for Clinical and Translational Science, University of Utah, 09/01/2010 - present. Total project budget to date: $37,500.00
  • Amphipathic oral chelators and radionuclide contamination. PI: Scott Miller. Co-PI(s): Xuli Wang. National Institute of Allergy and Infectious Diseases, 09/30/2006 - 09/29/2009. Total project budget to date: $1,905,800.00

Research Equipment and Testing Expertise

  • The following instruments are equipped in Dr. Wang’s Laboratory for Chemistry: HPLC (Agilent 1200), FT-IR (Varian 640), Chemical hoods (4X), UV-Vis spectrophotometer, Vacuum (4X), Rotary evaporator (Buchi), Ultrapure water purification system (Millipore), Vacuum concentrator, Freeze-dry system (Thermo Scientific).
  • The following instruments are available in Dr. Wang’s Laboratory for Bio-related studies: Cell culture hood, CO2 incubators, Microplate reader (Molecular Devices), GloMax multimode reader (Promega), Gel electrophoresis apparatus, UV transilluminator (UVP), Centrifuges, Scintillation counter (Beckman), -80°C ultrafreezer, Inverted light and fluorescence microscopes (Nikon).
  • Animal facilities: The Radiobiology Division has a dedicated animal facility which is located downstairs of Dr. Wang’s Laboratory. The animal facility includes 4 individual rodent rooms, cage cleaning room, and procedure suite.

Languages

  • Chinese, fluent.
  • English, fluent.

Publications

  • Xu R, Wang XL, Lu ZR. (2010). New Amphiphilic Carriers Forming pH-Sensitive Nanoparticles for Nucleic Acid Delivery. Langmuir. Published, 2010.
  • Wang XL, Xu RZ, Wu XM, Gillespie D, Jensen R, Lu ZR. (2009). Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Mol Pharm. Published, 2009.
  • Wang XL, Xu RZ, Lu ZR. (2009). A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. J Control Release, 134(3), 207-213. Published, 2009.
  • Zong Y, Wang XL, Jeong EK, Parker DL, Lu ZR. (2009). Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agent. Magn Reson Imaging, 27(4), 503-511. Published, 2009.
  • Wang XL, Nguyen T, Gillespie D, Jensen R, Lu Z. (2008). A Multifunctional and Reversibly Polymerizable Carrier for Efficient siRNA Delivery. Biomaterials, (29), 15-22. Published, 2008.
  • Ou M, Wang XL, Xu RZ, Kim SW. (2008). Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity. Bioconjug Chem, 19, 626-633. Published, 2008.
  • Kaneshiro T, Wang XL, Lu Z. (2007). Preparation and Investigation of Octa(3-aminopropyl) Silsesquioxane L-Lysine Dendrimers as Nucleic Acid Carriers. Mol Pharm, 4(5), 759-768. Published, 2007.
  • Ke T, Jeong E, Wang XL, Feng Y, Parker DL, Lu Z. (2007). RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker ανβ3 integrin with MR T1 mapping. Int J Nanomedicine, 2(2), 191-199. Published, 2007.
  • Yan GP, Wang XY, Wang XL, Huang SW, Zhuo RX. (2007). Synthesis and in vitro property study of polyaspartamides. Chin J Chem, 25(11), 1748-1753. Published, 2007.
  • Wang XL, Jensen R, Lu Z. (2007). A novel environment-sensitive biodegradable polydisulfide with protonatable pendants for nucleic acid delivery. J Control Release, 120(3), 250-258. Published, 2007.
  • Wang XL, Ramusovic S, Nguyen T, Lu Z. (2007). Novel Polymerizable Surfactants with pH-Sensitive Amphiphilicity and Cell Membrane Disruption for Efficient siRNA Delivery. Bioconjug Chem, (18), 2169-2177. Published, 2007.
  • Feng J, Wang XL He F, Zhuo Ren-Xi. (2007). Non-catalyst synthesis of functionalized biodegradable polycarbonate. Macromol Rapid Comm, 28(6), 754-758. Published, 2007.
  • Xu R, Wang Y, Wang XL Jeong E, Parker D, Lu Z. (2007). In Vivo Evaluation of PAMAM-Cystamine-(Gd-DO3A) Conjugate as a Biodegradable Macromolecular MRI Contrast Agent. Exp Biol Med, 232, 1081-1089. Published, 2007.
  • Ye F, Ke T, Jeong E, Wang XL, Sun Y, Johnson M, Lu Z. (2006). Noninvasive visualization of in vivo drug Delivery of Poly(L-glutamic acid) using contrast-enhanced MRI. Mol Pharm, 3(5), 507-515. Published, 2006.
  • Zhang XQ, Wang XL, Zhuo R, Zhang P, Leong K, Mao H. (2005). In Vitro Gene Delivery Using PAMAM Dendrimers With Trimesic Acid as Core. Biomacromol, 6(1), 341-350. Published, 2005.
  • Zhang XQ, Wang XL, Zhang P, Leong K, Mao H. (2005). Galactosylated Ternary DNA-polyphosphoramidate Nanoparticles Mediated High Gene Transfection in Hepatocytes. J Control Release, 102(3), 749-763. Published, 2005.
  • He F, Wang Y, Feng J, Zhuo R, Wang XL. (2003). Synthesis of poly[(5-benzyloxy-trimethylene carbonate)-co-(5,5-Dimethyl-trimethylene carbonate)] catalyzed by immobilized lipase on silica particles with different size. Polymer, 44(11), 3215-3219. Published, 2003.
  • Feng J, Zhuo R, He F, Wang XL. (2003). Synthesis of Functional Polycarbonates by Lipase-catalyzed Ring-opening Polymerization. Macromol Chem Phys, 195, 237-240. Published, 2003.
  • Wang XL, Huang S, Zhuo R, Liu L, He F. (2002). Synthesis, characterization and in vitro cytotoxicity of poly 5-benzyloxy-trimethylene carbonate-co-trimethylene carbonate. Macromol Chem Phys, 203(7), 985-990. Published, 2002.
  • Wang XL, Zhuo R, Liu L. (2002). Synthesis and characterization of novel aliphatic polycarbonates. J Polymer Sci Polymer Chem, 40(1), 70-75. Published, 2002.
  • Wang XL Zhuo R, Liu L. (2001). Synthesis and characterization of novel biodegradable poly(carbonate-co-phosphate)s. Polymer Int, 50(11), 1175-1179. Published, 2001.